Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Feb 06, 2020 11:53am

126 Views

Post# 30652290

RE:RE:RE:RE:RE:Much like Tesla

Risk management is different for everyone. So yes, I should sell now if I believe it will drop later. However,

1- I invest not day trade
2- I have big sharehold so no guarntee it would get filled at the price point i have in mind.
3- Its all in my tfsa, so do avoid getting audited if (when) it hits big, best to keep trades under a certain amount. Hence why I'm not selling. (yes i have that big of a sharehold)

Did that clear up the logic? (like presenting pearls before swine).

qwerty22 wrote:
So you're holding onto your stock tight at this price even though you know it's going down. And your telling others not to buy at this price. Where is the logic in that?

It seems reasonable to think that if they have strong data from this trial then they'll be heading for Ph3 talks with the regulators and partnering talks with big pharma. That's their plan. What market cap should the company be in advance of that process with the data in hand? $300 million USD? That would be my best guess atm. It all depends on how much value they can eventually unlock with the deal. Hopefully analysts will start to weigh in with their estimates on that point, the company is going to present its economic case soon. It's hard to see us still at present prices in that scenario. Obviously if the data is very bad this is going to zero. The gamble isn't really the daily price you buy at now it's the quality of the data from the trial and the long term consequences of that.

themagicbox wrote: LOL! holding on my shares with a kungfu grip. But get messages constantly from noob investors asking for advice.

Classic question: "should I buy at these prices?'

Short Reply:No!

Mickey2 wrote: thats because magixbox sold all his shares. Now some panic on his part as the stock price continues to ascend.